NCT00169000View on ClinicalTrials.gov

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

September 30, 2005

Study Completion Date

March 31, 2006

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Capecitabine

"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"

DRUG

Docetaxel

75 mg/m2 over one hour on day 8 of each cycle

Trial Locations (1)

03756

Norris Cotton Cancer Center, Lebanon

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00169000 - Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers | Biotech Hunter | Biotech Hunter